Smoking Cessation, Tobacco Use Cessation
Conditions
Brief summary
Financial incentives for motivating changes in health behavior, particularly for smoking and other morbid habits, are increasingly being tested by health insurers, employers, and government agencies. However, in using incentive programs for smoking cessation, key unanswered structural and theoretical questions remain regarding their effectiveness, acceptability to patients, and economic sustainability. This trial aims to advance the science and implementation of financial incentives for smoking cessation interventions among high-risk, hospitalized smokers. The investigators will pursue two specific aims: 1) comparing the impact of three approaches for smoking cessation on smoking abstinence, use of evidenced-based therapy, and quality of life and 2) comparing the short-term and long term return on investment of using goal directed and outcome-based financial incentives to promote smoking cessation.
Interventions
BEHAVIORALSmoking cessation counseling (Quitline)
Quitline offers community-based counseling session with a cessation counselor.
Participants will be encouraged to speak to their doctors about using highly effective pharmacotherapies for smoking cessation.
BEHAVIORALFinancial incentives for smoking cessation
Participants will receive financial incentives for bioconfirmed smoking cessation.
BEHAVIORALFinancial incentives for use of evidence-based smoking cessation therapies
Participants will receive financial incentives for the use of evidence-based smoking cessation therapies including Quitline counseling, community-based smoking cessation programs and pharmacotherapies
Sponsors
University of California, Los Angeles
NYU Langone Health
Olive View-UCLA Education & Research Institute
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. age ≥ 18 years 2. smoked tobacco during the prior 30 days, 3. have an active U.S. phone number and address, 4. can provide consent in English or Spanish and 5. are in at least the contemplative stage of change for quitting smoking, as assessed by a single measure, readiness to quit
Exclusion criteria
1. use only smokeless tobacco, 2. are pregnant or breastfeeding, 3. are discharged to an institution (e.g., nursing home, long-term care facility), 4. are unable to provide informed consent, or do not have cognitive ability to enroll or participate in the study
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Smoking abstinence assessed by self-report and biochemically verified by salivary cotinine | 6 months | Assessed by self-report questionnaire, and biochemically verified by salivary cotinine |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Use of evidence based treatment (e.g. counseling and smoking cessation medications) assessed by discharge prescriptions, Quitline records, receipts, letters and/or self-report | 2 months | Assessed by discharge prescriptions, Quitline records, receipts, letters and/or self-report |
| Quality of life as measured by PROMIS-29 Profile v2.0 | 12 months | Assessed by phone interviews. |
| Short term return on investment of using financial incentives to promote smoking cessation (Cost analysis) | 12 months | Cost analysis involving hospital utilization data, electronic health records and patient-reported healthcare utilization |
| Long term return on investment of using financial incentives to promote smoking cessation (Cost analysis) | 3 years | Cost analysis involving hospital utilization data, electronic health records and patient-reported healthcare utilization |
Countries
United States
Contacts
PRINCIPAL_INVESTIGATORJoseph Ladapo, MD, PhD
University of California, Los Angeles
PRINCIPAL_INVESTIGATORScott Sherman, MD
NYU Langone Health
Outcome results
None listed